Background
Higher dose (mg/day)* | Lower dose (mg/day)* | Systematic review [6]] | |||
---|---|---|---|---|---|
Paroxetine
| > 20 | ≤ 20 | • 20 – 50 mg/day | • 20 – 50 mg/day | • 20 – 50 mg/day |
• Reduce by 50% with CrCl < 30 ml/min | • Initiate at 10 mg/day with CrCl < 40 ml/min | • Initiate at 10 mg/day with eGFR < 60 ml/min | |||
Mirtazapine
| > 20 | ≤ 20 | • 15 – 45 mg/day | • 15 – 45 mg/day | • 15 – 45 mg/day |
• Use with caution with CrCl < 40 ml/min | • Use with caution | • Use with caution | |||
• Initiate at 15 mg/day with eGFR < 30 ml/min | |||||
Venlafaxine
| > 37.5 | ≤ 37.5 | • 75 – 225 mg/day | • 75 – 225 mg/day | • 75 – 225 mg/day |
• Reduce by 25 – 50% with CrCl 10 – 70 ml/min | • Reduce by 25 – 50% with GFR 10–70 ml/min | • Reduce to 37.5 mg/day with eGFR < 30 ml/min | |||
• Initiate at 37.5 mg/day |
Methods
Setting and study design
Data sources
Patients
Anti-depressant dose
Outcomes
Statistical analysis
Results
Higher dose | Lower dose | Standardized difference | |
---|---|---|---|
N = 36,651 | N = 81,160 | ||
Anti-depressant type,
n (%)
| |||
Paroxetine | 4,216 (11.5) | 41,889 (51.6) | 0.96 |
Mirtazapine | 9,531 (26.0) | 15,101 (18.6) | 0.18 |
Venlafaxine | 22,904 (62.5) | 24,170 (29.8) | 0.69 |
Demographics
| |||
Age, years, mean (SD)
| 73.7 (6.8) | 75.6 (5.8) | 0.29 |
Women, n (%)
| 22,472 (61.3) | 54,631 (67.3) | 0.13 |
Year of cohort entry,
n (%)
| |||
2002-2005 | 16,434 (44.8) | 4,2770 (52.7) | 0.16 |
2006-2009 | 14,661 (40.0) | 2,7984 (34.5) | 0.11 |
2010-2011 | 5,556 (15.2) | 10,406 (12.8) | 0.07 |
Income quintile,
n (%)
| |||
First (lowest) | 7,663 (20.9) | 16,725 (20.6) | 0.01 |
Second | 7,552 (20.6) | 17,627 (21.7) | 0.03 |
Third (middle) | 7,034 (19.20 | 16,003 (19.7) | 0.01 |
Fourth | 7,118 (19.4) | 15,226 (18.8) | 0.02 |
Fifth (highest) | 7,142 (19.5) | 15,327 (18.9) | 0.02 |
Missing | 142 (0.4) | 252 (0.3) | 0.01 |
Rural Location,
n (%)
| 5,386 (14.7) | 10,943 (13.5) | 0.03 |
Modified Charlson score
Ŧ
,
n (%)
| |||
0 or no hospitalization | 25,360 (69.2) | 56,063 (69.0) | 0.00 |
1 | 4,263 (11.6) | 9,548 (11.7) | 0.00 |
2 | 3,514 (9.6) | 7,571 (9.3) | 0.01 |
≥3 | 3,514 (9.6) | 8,005 (9.9) | 0.01 |
Co-morbidities
£
,
n (%)
| |||
Chronic liver disease | 1,348 (3.7) | 2,970 (3.7) | 0.00 |
Chronic kidney disease* | 1,609 (4.4) | 3,772 (4.7) | 0.01 |
Chronic obstructive pulmonary disease | 1,849 (5.0) | 4,389 (5.4) | 0.02 |
Coronary artery disease¶
| 12,951 (35.3) | 31,350 (38.6) | 0.07 |
Heart failure | 4,133 (11.3) | 10,715 (13.2) | 0.06 |
Stroke/Transient ischemic attack | 1,148 (3.1) | 2,625 (3.2) | 0.01 |
Diabetes mellitus (on medication)+
| 5,878 (16.0) | 12,203 (15.0) | 0.03 |
Medication
¥
,
n (%)
| |||
Anticonvulsants | 3,728 (10.2) | 6,574 (8.1) | 0.07 |
Gabapentin | 363 (1.0) | 525 (0.7) | 0.04 |
Antipsychotics | 2,499 (6.8) | 3,752 (4.6) | 0.09 |
Barbiturates | 89 (0.2) | 163 (0.2) | 0.01 |
Benzodiazepines | 15,736 (42.9) | 35,681 (44.0) | 0.02 |
Histamine2-receptor antagonists | 3,417 (9.3) | 9,764 (12.0) | 0.09 |
Dopamine agonists | 298 (0.8) | 517 (0.6) | 0.02 |
Muscle relaxants | 311 (0.9) | 564 (0.7) | 0.02 |
Opioids | 10,408 (28.4) | 21,632 (26.7) | 0.04 |
Overactive bladder medications | 1,424 (3.9) | 2,992 (3.7) | 0.01 |
Prescribing physician,
n (%)
| |||
General practitioner | 27,884 (76.1) | 62,622 (77.2) | 0.03 |
Internist | 251 (0.7) | 669 (0.8) | 0.02 |
Neurologist | 179 (0.5) | 408 (0.5) | 0.00 |
Other | 3,514 (9.6) | 6,354 (7.8) | 0.06 |
Missing | 4,823 (13.2) | 11,107 (13.7) | 0.02 |
30-day hospitalization with urgent head Computed Tomography (CT) scan
Number of events, n (%)
| Relative risk (Unadjusted) | Relative risk (Adjusted) | Absolute risk reduction (%) | ||
---|---|---|---|---|---|
Higher dose£
| Lower dose¶
| (95% CI) | (95% CI)¥
| ||
(95% CI) | |||||
N = 36,651 | N = 81,160 | ||||
Hospital admission with head CT scan
| 400 (1.09) | 1,033 (1.27) | 0.86 (0.76 – 0.96) | 0.90 (0.80 – 1.02) | (…) |
All-cause mortality
| 278 (0.76) | 791 (0.97) | 0.78 (0.68 – 0.89) | 0.82 (0.71 – 0.95) | 0.22 (0.10 – 0.33) |